David Fanning has over 20 years of combined experience in pharmaceuticals and corporate management. Prior to Spaltudaq, he served as Chief Operating Officer of Seattle-based Corixa Corporation from 2001 to 2005. During that time, Mr. Fanning was responsible for business development, manufacturing, commercial operations, and program management. Corixa was acquired by GlaxoSmithKline in July of 2005. From 2000 to 2001, Mr. Fanning was Chief Business Officer for CoPharma, Inc. of Hopkinton, MA. And, from 1997 to 2000, served as Vice President, Business Development and Marketing for Corixa. From 1995 to 1997, Mr. Fanning worked in business development at CytoTherapeutics, Inc. (currently, Stem Cells, Inc.) and led the formation of Modex Therapeutiques, SA in Lausanne. From 1988 to 1995, Mr. Fanning was a consultant in the Tokyo and Cambridge offices of The MAC Group/ Gemini Consulting (currently, Cap Gemini Ernst & Young). Mr. Fanning received his AB from Harvard University and his SM in Management from the MIT Sloan School of Management.